珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function
2026年10月29日 17:50:01来源:作者:
【摘要】 Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based mediaDARMSTADT, Germany--(
  • Improvements in symptoms of pain, stiffness, and range of motion were sustained through two years
  • Tumor responses remained robust1 and durable2

Not intended for U.K.-, U.S.- or Canada-based media

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P).

"For people living with TGCT, the impact of the disease is often felt through persistent limitations in mobility, physical function and the ability to carry out everyday activities," said Vinod Ravi, MD, MS, MBA, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, an investigator on the MANEUVER trial. "What is encouraging about these two-year findings is the consistency of improvements, not only in the durability of tumor response, but across the symptoms and functional outcomes that matter to patients. Together with the observed safety profile, these results provide important insight into the potential for pimicotinib to deliver meaningful benefit over time."

The new analysis in patients initially randomized to pimicotinib found that at Week 97, mean changes from baseline were 19.6% in range of motion, -3.9 in stiffness (as measured by the Worst Stiffness Numeric Scale Rating), -3.1 in pain (as measured by the Brief Pain Inventory worst pain rating) and +7.4 in physical function (as measured by the patient-reported PROMIS-PF scale).

Tumor responses also remained robust1 and durable2 through two years. Objective Response Rate (ORR) by blinded independent review committee (BICR) per RECIST v1.1 was 76.2% (95% CI: 63.8, 86.0), remaining unchanged from the one-year analysis, while ORR per BIRC based on tumor volume score (TVS) increased from 74.6% at one year to 77.8% (95% CI: 65.5, 87.3) at two years. Median duration of response was not reached at the time of analysis, and median treatment duration was 22.6 months (range: 1.8-33.6 months) at the March 1, 2026 data cutoff. Fifty-four percent of patients initially randomized to pimicotinib remained on treatment at two years.

In MANEUVER, pimicotinib was well-tolerated, with no evidence of cholestatic hepatotoxicity or hair/skin hypopigmentation. During the randomized, double-blind treatment phase of the trial, treatment-emergent adverse events (TEAEs) leading to treatment discontinuation occurred in one patient (1.6%) treated with pimicotinib; TEAEs leading to dose reduction occurred in 7.9% (n=5) of pimicotinib-treated patients.

"These two-year findings add to the growing body of evidence from the MANEUVER study demonstrating the potential for pimicotinib to meaningfully address some of the burden of TGCT," said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The sustained improvements observed across symptoms, physical function and tumor control reinforce the potential of pimicotinib to address aspects of TGCT that can affect patients every day. These results add to our evolving understanding of the long-term benefit that pimicotinib may provide for people living with this debilitating rare tumor."

TGCT is a rare, locally aggressive tumor occurring in or around the joints leading to progressive worsening of symptoms including pain and reduced mobility of the affected joint, significantly impacting physical function in what is typically an otherwise healthy and young adult population. Patient-reported experiences indicate that up to half of people with TGCT may initially receive an incorrect diagnosis, which can delay appropriate disease management.3 If left untreated or in recurrent cases, TGCT may result in cumulative morbidity and irreversible damage to the bone, joint and surrounding tissues.

Pimicotinib was approved in China by the China National Medical Products Administration (NMPA) in December 2025 and in Canada by Health Canada in June 2026 for the treatment of adult patients with symptomatic TGCT. A regulatory application is currently under review by the U.S. Food and Drug Administration (FDA) and other regulatory agencies.

1 54% ORR as assessed by BIRC based on RECIST v1.1 at week 25 vs. 3% with placebo; p<0.0001.

2 The majority (77%) of patients with response at 25 weeks maintained this clinical benefit after an additional 12 months of treatment.

3 Stern S, et al. Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry. Future Oncol. 2025;21(12):1501-1510.

 

责任编辑: admin

看新闻,关注新闻

天猫网友:余存° d3sTiny-
评论:等我死了,我就让我儿子给我放潇洒走一回

百度网友:以死换温柔◇
评论:别以为遇见我就是你旳缘,也可能是你旳坎。

搜狐网友:相依°- Janet
评论:我妈就生了这么一个限量版的我,你看着办吧Q_Q

天涯网友:- 莫失莫忘/ 
评论:如果我死了,唯一放不下的就是我的QQ。

其它网友:红酒 高跟鞋 性感seduce
评论:在混乱中成长;在成长中乱混。

腾讯网友:有你灬我很幸福
评论:梦想是用来破灭的,不是用来实现的,因为在现实面前,它就是一个屁。

本网网友:memory’流年
评论:古希腊人说过:能让我笑得人最爱我,能让我哭的人我最爱。

淘宝网友:゛风骚, - /ov3
评论:其实我感觉我的身材蛮好的嘛?肥而不腻

网易网友:女人要自爱
评论:人不如己,尊重别人,己不如人,尊重自己。

凤凰网友:想哭卻無淚
评论:人=吃饭+睡觉+上班+玩,猪=吃饭+睡觉 ∴人=猪+上班+玩 ∴人-玩=猪+上班,不懂玩的人=会上班的猪

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!